Inhibition of neointima formation through DNA vaccination for apolipoprotein(a): A new therapeutic strategy for lipoprotein(a)

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Kyutoku, Mariko ^a,b   Nakagami, Hironori ^b   Koriyama, Hiroshi ^a,b   Nakagami, Futoshi ^a,b   Shimamura, Munehisa ^b   Kurinami, Hitomi ^b   Tomioka, Hideki ^a,b   Miyake, Takashi ^a   Katsuya, Tomohiro ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; DNA VACCINE; LIPOPROTEIN A;

ANIMAL; ARTICLE; FEMALE; GENE THERAPY; GENETICS; METHODOLOGY; MOUSE; NEOINTIMA; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; APOLIPOPROTEINS A; FEMALE; GENETIC THERAPY; LIPOPROTEIN(A); MICE; MICE, TRANSGENIC; NEOINTIMA; TREATMENT OUTCOME; VACCINES, DNA;

EID: 84876580155     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01600     Document Type: Article

References (46)

1. Berg, K. A new serum type system in man-the Lp system. Acta Pathologica Microbiologica Scandinavica 59, 369-382 (1963).
2. Eaton,D. L. et al. Partial amino acid sequence of apolipoprotein (a) shows that it is homologous to plasminogen. Proc. Natl Acad. Sci. USA 84, 3224-3228 (1987). (Pubitemid 17085377)
3. McLean, J. W. et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 330, 132-137 (1987). (Pubitemid 17158542)
4. Miles, L. A., Fless, G. M., Levin, E. G., Scanu, A. M. & Plow, E. F. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature 339, 301-303 (1989). (Pubitemid 19130695)
5. Scanu, A. M. & Fless, G. M. Lipoprotein (a). Heterogeneity and biological relevance. J. Clin. Invest. 85, 1709-1715 (1990). (Pubitemid 20192939)
6. Brown, G. et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N. Engl. J. M ed. 323, 1289-1298 (1990). (Pubitemid 20364735)
7. Taylor, A. J. et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. M ed. 361, 2113-2122 (2009).
8. Nakagami, F. et al. Estrogen attenuates vascular remodeling in Lp (a) transgenic mice. Atherosclerosis 211, 41-47 (2010).
9. Morgan, D. et al. Ab peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985 (2000). (Pubitemid 32101645)
10. Schenk, D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3, 824-828 (2002). (Pubitemid 135706694)
11. Tissot, A. C. et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebocontrolled phase IIa study. Lancet 371, 821-827 (2008). (Pubitemid 351323893)
12. Ishii, K. J. et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451, 725-729 (2008). (Pubitemid 351220566)
13. Pumpens, P. & Grens, E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44, 98-114 (2001). (Pubitemid 32757388)
14. Yamada, S. et al. A new Lp (a) assay that is unaffected by apo (a) size polymorphism. Clinica chimica acta 287, 29-43 (1999). (Pubitemid 29413007)
15. Frazer, K. A., Narla, G., Zhang, J. L. & Rubin, E. M. The apolipoprotein (a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat. Genet. 9, 424-431 (1995).
16. Lawn, R. M. et al. Atherogenesis in transgenic mice expressing human apolipoprotein (a). Nature 360, 670-672 (1992). (Pubitemid 23007679)
17. Callow, M. J., Stoltzfus, L. J., Lawn, R. M. & Rubin, E. M. Expression of human apolipoprotein B and assembly of lipoprotein (a) in transgenic mice. Proc. Natl Acad. Sci. USA 91, 2130-2134 (1994). (Pubitemid 24092056)
18. Morishita, R. et al. Impairment of collateral formation in lipoprotein (a) transgenic mice. Circulation 105, 1491-1496 (2002).
19. Jürgens, G. et al. Lipoprotein (a) serum concentration and apolipoprotein (a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 26, 1841-1848 (1995).
20. Willeit, J. et al. Lipoprotein (a) and Asymptomatic Carotid Artery Disease Evidence of a Prominent Role in the Evolution of Advanced Carotid Plaques: The Bruneck Study. Stroke 26, 1582-1587 (1995).
21. Schaefer, E. J. et al. Lipoprotein (a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271, 999-1003 (1994).
22. Budde, T. et al. Plasma Lp (a) levels correlate with number, severity, and lengthextension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscl. Throm, Vas 14, 1730-1736 (1994).
23. Terres, W. et al. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a). Circulation 91, 948-950 (1995).
24. Bostom, A. G. et al. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 276, 544-548 (1996). (Pubitemid 26272299)
25. Callow, M., Verstuyft, J., Tangirala, R., Palinski, W. & Rubin, E. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J. Clin. Invest. 96, 1639-1646 (1995).
26. Kojima, S., Harpel, P. C. & Rifkin, D. B. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J. Cell Biol. 113, 1439-1445 (1991). (Pubitemid 21909770)
27. Grainger, D. J. et al. Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science 260, 1655-1658 (1993). (Pubitemid 23247149)
28. Grainger, D. J., Kemp, P. R., Liu, A. C., Lawn, R. M. &Metcalfe, J. C. Activation of transforming growth factor-b is inhibited in transgenic apolipoprotein (a) mice. Nature 370, 460-462 (1994). (Pubitemid 24263550)
29. Daida, H. et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Ame. J. Cardiol. 73, 1037-1040 (1994). (Pubitemid 24175506)
30. Yamaguchi, H. et al. Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL-apheresis angioplasty restenosis trial (L-ART). Chem. Phys.Llipids 67, 399-403 (1994). (Pubitemid 24054500)
31. Hajjar, M. K. A. & Nachman, M. R. L. The role of lipoprotein (a) in atherogenesis and thrombosis. Annu. Rev. Med. 47, 423-442 (1996).
32. Dillman, R. O. Cancer immunotherapy. Cancer Biother. Radio. 26, 1-64 (2011).
33. Delavallée, L., Duvallet, E., Semerano, L., Assier, E. & Boissier, M.-C. Anticytokine vaccination in autoimmune diseases. Swiss Med. WKLY 140, w13108 (2010).
34. Schenk, D. Amyloid-b immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3, 824-828 (2002). (Pubitemid 135706694)
35. Schenk, D. et al. Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 400, 173-177 (1999). (Pubitemid 29327547)
36. Orgogozo, J. M. et al. Subacute meningoencephalitis in a subset of patients with AD after Ab42 immunization. Neurology 61, 46-54 (2003).
37. Ferrer, I., Rovira, M. B., Guerra, M. L. S., Rey, M. J. & Costa-Jussá, F. Neuropathology and Pathogenesis of Encephalitis following Amyloid b Immunization in Alzheimer's Disease. Brain Pathol. 14, 11-20 (2006).
38. Nicoll, J. a. R. et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448-452 (2003).
39. Broytman, O. & Malter, J. S. Anti-Ab: The Good, The Bad, and The Unforeseen. J. Neuro. Res. 306, 301-306 (2004).
40. Agadjanyan, M. G. et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from b-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174, 1580-1586 (2005).
41. Gardiner, S. M. et al. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Brit. J. Phamacol. 129, 1178-1182 (2000). (Pubitemid 30153974)
42. Cribbs, D. H. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 15, 505-514 (2003). (Pubitemid 36432403)
43. Yip, H. C. et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 162, 3942-3949 (1999).
44. Brown, M. J. et al. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin. Sci. 107, 167-173 (2004). (Pubitemid 39070933)
45. Ambühl, P. M. et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J. Hypertension 25, 63-72 (2007). (Pubitemid 44885665)
46. Thomas, L. J. et al. Co-administration of a CpG adjuvant (VaxImmuneTM, CPG 7909) with CETP vaccines increased immunogenicity in rabbits andmice. Human Vaccines 5, 79-84 (2009).